Hong Kong-based CER Research Friday said Abbott Laboratories Inc.'s (ABT: Quote) response to the report released March 22 relating to the safety of the infant formula product Similac Stage 1 was "irresponsible." The report contained results which showed that the Abbott product, purchased in Hong Kong in December, failed two tests by a significant margin.
In its response, which, according to CER Research, was issued in Chinese, Abbott criticized the report for a lack of "scientific-ness, objectivity and fairness." CER Research's rebuttal claims that the results were obtained from "named and recognized laboratories and experts", adding that it has "no independent view" on the product. Further, CER Research said its attempts to contact Abbott were rebuffed.
Click here to receive FREE breaking news email alerts for Abbott Laboratories and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com
Business News